FASE 2 - CPHG: Initial findings of an observational study of patients with severe asthma treated in French non-academic hospitals.

After FASE-CPHG which had included 1502 patients in 2016, we launched a new observational study of patients with severe asthma in French nonacademic hospitals in 2022. 1031 patients were screened, 1002 included and 970 analyzed, women: 66%, men: 34%, mean age 54.5 y (+/-15.8). Among them, 57% presented an ENT disease (nasal polyposis: 27%). Other comorbidities were: GERD (35%), obesity (32%), high BP (25 %), obstructive sleep apnea syndrome (17%), diabetes (13%) and Samter’s triad (8%). Anxiety was present in 26.5% and depression in 10.7% of patients. Median FEV1 was 74.7% (+/-22.5). Allergologic assessment by prick-tests was performed in 62% of patients and positive in 67%. Blood eosinophils count was measured in 85.5% of cases with a mean value of 601 (+/-653) G/L. The mean number of exacerbations on the last 12 months was 2.1 +/-3.5. 40% of patients were frequent exacerbators. A combination of CSI/LABA was given in 93%, mean dose of CSI was 1453 ug/d (+/-1521). 12% received long term oral corticosteroids (mean dose of 10 mg/d). Due to exacerbations, 29% received a short course of CSO on the last 12 months (cumulative dose = 880 +/-1138 mg). 11% of patients received a low dose of ICS, 8% a medium dose and 81% a high dose. 83% of patients were treated with biologics: anti-IgE: 35%, anti-IL-5: 24%, anti-IL-5R: 22% and anti-IL -4/IL-13: 18%. According to the Girerd’s score, treatment compliance was good for 32%, intermediate for 57% and poor for 12% of patients. Despite all these treatments, asthma was uncontrolled in 62%, moderately controlled in 29% and well controlled in only 12% of patients. With this large population of more than 1000 patients, FASE 2 - CPHG refines the description of patients with severe asthma followed in French non-academic hospitals.